NASDAQ:TARS
Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals, Inc.'s revenue grew 146.7% in fiscal 2025 to $451.4M while operating margin rose to −15.7%, its highest in 5 years. Free cash flow was −$22.3M, −4.9% of revenue, and the diluted share count rose 11.1%.Summary generated from Tarsus Pharmaceuticals, Inc.'s SEC filings. Latest annual report filed Feb 23, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$451.4M
Revenue growth+146.7%
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating margin−15.7%
Net margin−14.7%
ROIC−25.8%
Return on equity−23.4%
Debt / equity0.21
Free cash flow−$22.3M
FCF margin−4.9%
Share count change+11.1%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 57 | 26 | 17 | 183 | 451 |
| Operating income | −12 | −63 | −143 | −121 | −71 |
| Net income | −14 | −62 | −136 | −116 | −66 |
| Free cash flow | 3 | −50 | −119 | −85 | −22 |
Recent filings
- 4Insider transaction report
Sep 17, 2026 - 4Insider transaction report
Sep 17, 2026 - 8-KCompletion of an acquisition or disposition
Sep 10, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 6, 2026 - 8-KResults of operations and financial condition
Aug 6, 2026 - 8-KEntry into a material agreement
Aug 6, 2026 - 8-KEntry into a material agreement
Aug 6, 2026 - 8-KDirector or officer change
Jul 13, 2026